Addiction treatment in Texas

The Texas you find in addiction-treatment data is not the Texas you see on a map. 733 licensed facilities do not distribute evenly; access varies block by block, insurance by insurance, month by month. This page walks through the state as someone weighing the decision actually experiences it.

The Medicaid question

Texas has not expanded Medicaid under the Affordable Care Act. What that means in practice: a low-income adult in Texas with substance use disorder typically falls into the eligibility gap — income too high for traditional Medicaid, too low to qualify for substantial Marketplace subsidies. This is the single largest variable in whether treatment is financially reachable — larger than any specific facility's sliding-scale policy or any commercial plan's network.

The overdose-mortality context

The raw number — 16.0 overdose deaths per 100,000 in Texas — matters less than what it tells you about where treatment could intervene. Most deaths involve opioids, and most opioid deaths in the state now involve illicitly manufactured fentanyl. That is the single biggest shift in the clinical landscape since 2015, and it is the thing treatment programs in Texas have had to adapt to.

How access actually works in Texas

Access in Texas favors patients who know which questions to ask. largest Medicaid-eligibility-gap population in the country For most people the useful first step is not the closest facility but the most honest evaluation: a primary-care doctor, a licensed substance-use counselor, or the SAMHSA helpline (1-800-662-HELP) can help decide what level of care is actually warranted before the facility search narrows.

What to do next

The steps that help most families in Texas are not the ones that feel most productive. Calling ten facilities and collecting brochures often produces worse results than a single honest conversation with a primary-care doctor, a licensed substance-use counselor, or a trusted clinician who can refer into Texas's specific treatment network. Start with someone whose incentives are clinical, not commercial.